Domestic pharmaceutical companies win Trajenta’s crystalline patent nullification trial
Domestic pharmaceutical companies have won the crystalline patent nullification trial of ‘Trajenta,’ a new DPP-4 type antidiabetic.
Including Trajenta Duo, Trajenta imported by Boehringer and sold by Yuhan Corporation is a large drug recording annually KRW 97.2 billion last year.
Domestic compa...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
